biotech · PTSD - Post Traumatic Stress Disorder · P1b: Advanced Solid Tumors · CMPX
Compass Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Compass Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L01) compound in Compass Therapeutics's portfolio. Molecular target: Tyrosine-protein kinase ABL1.
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.